Lazabemide
Jump to navigation
Jump to search
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C8H10ClN3O |
Molar mass | 199.64 g·mol−1 |
Lazabemide (proposed trade names Pakio, Tempium) is a reversible and selective inhibitor of monoamine oxidase B (MAO-B) that was under development as an antiparkinsonian agent but was never marketed.[1]
References
- ^ Henriot S, Kuhn C, Kettler R, Da Prada M (1994). "Lazabemide (Ro 19-6327), a reversible and highly sensitive MAO-B inhibitor: Preclinical and clinical findings". Amine Oxidases: Function and Dysfunction. Vol. 41. pp. 321–325. doi:10.1007/978-3-7091-9324-2_42. ISBN 978-3-211-82521-1. PMID 7931245.
{{cite book}}
:|journal=
ignored (help)
Categories:
- CS1 errors: periodical ignored
- Articles with short description
- Short description matches Wikidata
- Drugs not assigned an ATC code
- Drugs with non-standard legal status
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Articles containing unverified chemical infoboxes
- Abandoned drugs
- Monoamine oxidase inhibitors
- Chloroarenes
- Pyridines
- Carboxamides
- All stub articles
- Nervous system drug stubs